Kenneth Pienta - Dec 20, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
Chief Medical Officer
Signature
/s/ Kenneth Pienta by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Dec 20, 2021
Transactions value $
$0
Form type
4
Date filed
12/21/2021, 03:05 PM
Next filing
Mar 29, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Award $0 +80K $0.00 80K Dec 20, 2021 Common Stock 80K $11.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 This stock option grant becomes exercisable in four equal semi-annual installments beginning June 20, 2022.